Medical effects of internal contamination with uranium

Croatian Medical Journal

Volumn 40, Issue 1, 1999, Pages 49-66

  Duraković, Asaf ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Actinides; Carcinogens; Dose response relationship, Gulf War syndrome; Mutagenesis; Mutation; Nuclear decoy; Radioactivity; Radiobiology; Uranium

Indexed keywords

ACTINIDE; CHELATING AGENT; CITRIC ACID; DEFEROXAMINE; EDETIC ACID; EMETIC AGENT; LAXATIVE; PENTETIC ACID; URANIUM; URANIUM 238;

ARTICLE; CARCINOGENICITY; HALF LIFE TIME; HUMAN; INTESTINE ABSORPTION; INTOXICATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MUTAGENIC ACTIVITY; NEPHROTOXICITY; NUCLEAR INDUSTRY; ORAL DRUG ADMINISTRATION; PERSIAN GULF SYNDROME; RADIOACTIVE CONTAMINATION; STOMACH LAVAGE;

ANIMALS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTION; HUMANS; RADIOACTIVE WASTE; URANIUM;

EID: 0032906514     PISSN: 03539504     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (148)

1. Gindler JE, Huisenga JR. Nuclear fission. In: Yaffe L, editor. Nuclear chemistry: vol. 2, New York, London: Academic Press; 1968. p. 1-183.
2. Schmorak MR. Nuclear data sheets. Nuclear data, vol. B4, No. 6. Berkeley (CA): University of California; 1960.
3. Skarswag K, Bergheim K. Energy and angular distribution of prompt neutrons from slow neutron fission of U-235. Nuclear Physics 1963;45:72-97.
4. Cordfunke EHP. The chemistry of uranium. Amsterdam-New York-London: Elsevier Publishers; 1969.
5. Wilkinson WD. Uranium metallurgy. Vol. 1: Uranium process metallurgy, New York-London: Interscience Publ; 1962.
6. Sato A. Studies of the behavior of trivalent uranium in an aqueous solution. 1. Its reduction and stability in various acid solutions. Bulletin of the Chemical Society of Japan 1967;40:2107-10.
7. Nemodruck AA, Palei PN. A photometric study of the interaction of tetravalent uranium with arsenazo-3. Zhournal Analiticheskoi Kimii (Journal of Analytical Chemistry, USSR) 1963;18:416-20.
8. Pitts RF, Lotspeich WD. The renal excretion and reabsorption of bicarbonate. Fed Proc 1946;5:182-97.
9. Hodge HC. Mechanisms of uranium poisoning. Proceedings of International conference for peaceful uses of atomic energy; 1955; Geneva, Switzerland. New York: United Nations; 1956;13:229-32, P/73.
10. Chernyaev II. Complex compounds of uranium. Moscow: Izdatelstvo "Nauka"; 1964. New York: Daniel Devy and Co. Inc; 1966.
11. Voegtlin C, Hodge HC. Pharmacology and toxicology of uranium compounds. Vol. 1 and 2. New York, Toronto, London: McGraw Hill; 1949.
12. Hodge HC, Maynard EA, Downs WL. Antidotal action of polyphosphates in uranium poisoning. J Pharmacol Exp Ther 1951;101:17-8.
13. Neuman WF, Flemming RW, Dounce AL, Carlson AB, O'Leary J, Mulryan. The distribution and excretion of injected uranium. J Biol Chem 1948;175:705-9.
14. Rajan KS, Martell AE. Equilibrium studies of uranyl complexes. Interaction of uranyl ion with citric acid. Inorganic Chemistry 1964;26:1927-44.
15. Lusky LM, Braun HA. Sodium catechol disulphonate protection in experimental uranium-nitrated poisoning. Fed Proc 1950;9:297-9.
16. Dagimanjian R, Maynard EA, Hodge HC. The effect of calcium disodium ethylene diamine tetraacetate on uranium poisoning in rats. J Pharmacol Exp Ther 1956;117:20-8.
17. Catsch A. Die wirkung einiger chelatbildner auf die akute toxcitat von uranylnitrat. Klin Wochenschrift 1959;37:657-60.
18. Catsch A. Radioactive metal mobilization in medicine. Springfield (IL): C.C. Thomas Publishing Co; 1964.
19. Ivannikov AJ. Physiochemical approaches to the selection of organic compounds designed to eliminate radioactive substances from the organism. Washington DC: Atomic Energy Commission; 1966. tr. 6944, p. 581-91. (Translated from: Razbitnaya LM, Smolin DD, Razumovskiy NO, Torchinskaya OL, editors. Raspredelenye i biologicheskoye deistviye radioaktivnih izotopov. Moscow: Atomizdat; 1966. p. 462-70.)
20. Ivannikov AJ. Physiochemical approaches to the selection of organic compounds designed to eliminate radioactive substances from the organism. Washington DC: Atomic Energy Commission; 1966. tr. 6944, p. 581-91. (Translated from: Razbitnaya LM, Smolin DD, Razumovskiy NO, Torchinskaya OL, editors. Raspredelenye i biologicheskoye deistviye radioaktivnih izotopov. Moscow: Atomizdat; 1966. p. 462-70.)
21. Stannard JN. Biomedical aspects of plutonium (discovery, development, projections). In: Hodge HC, Stannard JN, Hursh JB, editors. Uranium-plutonium-transplutonic elements. Berlin, Heidelberg, New York: Springer-Verlag; 1973. p. 308-688.
22. Rosenthal MW, Lindenbaum A. Osteosarcomas as related to tissue distribution of monomeric and polymeric plutonium in mice. In: Mays CW, Jee WSS, Lloyd RD, Stover BJ, Dougherty JH, Taylor GN, editors. Delayed effects of bone-seeking radionuclides. Salt Lake City (UT): University of Utah Press; 1969. p. 371-84.
23. Stevens W, Bruenger EW, Stover BJ. In-vivo studies on the interactions of Pu-IV with blood constituents. Radiat Res 1968;33:400-500.
24. 241Am in the adult baboon. Radiat Res 1973;55:129-43.
25. Durbin PW. Plutonium in mammals: influence of plutonium chemistry, route of administration and physiological status of the animals on initial distribution and long term metabolism. Health Physics 1975;29:495-510.
26. Naryani PS, Wrenn E. Tracers and methods for determining thorium and uranium in biological samples. In: Wrenn ME, editor. Actinides in man and animals. Salt Lake City (Ut): RD Press; 1981. p. 53-68.
27. Gmelin CG. Versuche über die wirkungen des bartis strontians, chroms, molybdäns, wolframs, tellurs, titans osmiums, platins, iridiums, rhodiums, paladiums, nikels, kobalts, urans, ceriums, eisens und mangans auf den tierishen Organismus. Journal für Chemie und Physik (Halle) 1825;43:110-5.
28. LeConte C. Résumé des experiences sur l'azotate d'uranium. Compte rendus des seances de la societe de biologie et des filiales (Paris) 1853;5:171-3.
29. Bradford FS. Case from practice. North American Homeopathy Journal 1860;8:502-3.
30. Hughes R. On the nature and treatment of diabetes. British Journal of Homeopathy 1866;24:253-69.
31. Luessentrop AJ, Gallimore JC, Sweet WH, Struxness EG, Robinson J. The toxicity in man of hexavalent uranium following intravenous administration. American Journal of Roentgenology, Radium Therapy and Nuclear Medicine 1958;79:83-100.
32. Kobert R. Lehrbuch der intoxikationen. Vol. 2. Stuttgart: Ferdinand Enke Publishing Co; 1906, 321-3.
33. Autenrith W, Warren WH. Laboratory manual for the detection of poisons and powerful drugs. 6th American ed. Philadelphia (PA): Blakiston's Son & Co; 1928.
34. Dünner L. Über des Wesen der experimentellen, ausschwemmungs nephritis nach uranvergiftung. Zeitschrift für klinische Medizin 1914-1915;81:355-76.
35. Sachs I. Die Wirkung des Ephedrins auf den Ablauf der Urannephritis. Archiv des exerimentellen pathologische Anatomie 1922;238:325-58.
36. Hess L, Wiesel J. Über die Wirkung von adrenalin bei akuten experimentellen nephropathien. Wien Klin Wochenschr 1914;81:355-9.
37. Chittenden RH, Lambert A. Untersuchungen über die physiologische wirkung der uransalze. Zeitschrift für Biologie 1889;25:513-32.
38. Aschoff L. The pathogenesis of the contracted kidney. Arch Intern Med 1913;12:723-38.
39. Baehr G. Über experimentelle glomeruloephritis. Beitrage zur pathologischen Anatomie und zur algemeinen Pathologie 1912;55:545-74.
40. MacNider W, De B. The functional and pathological response of the kidney in dogs subjected to a second subcutaneous injection of uranium nitrate. J Exp Med 1929;49:411-34.
41. Duraković A. Internal contamination with radionuclides. In: Conklin JJ, Walker RI, editors. Military radiobiology. Orlando, Toronto: Academic Press, Inc; 1987. p. 241-2.
42. Watanabe CK. A comparative study of the rate of excretion of the nitrogenous waste products to their blood concentration in experimental uranium nephritis. J Urol 1917;1:485-94.
43. Donnelly GL, Holman RL. The stimulating influence of sodium citrate on cellular regeneration and repaid in the kidney injured by uranium nitrate. J Pharmacol Exp Ther 1942;75:11-7.
44. Nuzum IR, Rothschild LL. Experimental serum nephritis. Arch Intern Med 1923;31:894-904.
45. Traissac FJ. Les lesions du foie dans l'intoxication experimentelle du lapin par nitrate d'uran. Comptes rendus des seances de la societe de biologie et des filiales (Paris) 1933;112:875-6.
46. Deveze R. L'aminoacidurie et l'ammoniurie au cours de la nephrite uranique aiuque chez le chien, lapin et le rat. Comptes rendus des seances de la societe de biologie et des filiales (Paris) 1934;117:1113-4.
47. De Laet M, Meurice C. Etude sur la pathologie profesionelle de l''uranium. Ingénier chimiste (Brussels) 1925;9:257-62.
48. Brull L. Reversibilitié de l'acidose de la néphrite aigna au nitrate d'urane. Comptes rendus des seances de la societe de biologie et des filiales (Paris) 1935;118:811-2.
49. Brull L, Fanielle G. Etude experientale de la nephrite uranique. Archives internationales de pharmacodynamie et de therapie 1932;42:1-38.
50. Larson HW. Xylose tolerance of rabbits with uranium nephritis. J Lab Clin Med 1923;22:117-25.
51. Hodge HC. Mechanism of uranium poisoning. Archives of Industrial Health 1956;14:43-7.
52. Karsner HT, Reiman SP, Brooks SC. Studies on uranium poisoning, the toxicity of certain water-soluble salts of uranium. Journal of Medical Research 1919;39:157-61.
53. Verne J. Lesions histologiques des centres nerveux superieurs chez le lapins soumis a l'intoxication chronique part l'urane. Annales d'anatomie pathologique 1931;8:757-8.
54. Zwaardemarker H. On physiological radioactivity. J Physiol 1919-1920;53:273-89.
55. Ford MR. Comments on intake guides for various isotopes or isotopic mixtures of uranium. Oak Ridge (TN): Union Carbide Corporation; 1964.
56. Fusamura N, Misawa H. Measurements of radioactive gas and dust as well as the investigation of their prevention in Japanese uranium mines. In: International Atomic Energy Agency. Radiation health and safety in mining and milling of nuclear materials. Vienna: IAEA;1964: p. 391-9.
57. Raabe OG, Wrenn MDE. Analyses of radon daughter activities by weighted least squares. Health Phys 1969;17:598-604.
58. Marks S. An introduction to the US Uranium Registry. In: Wren ME, editor. Actinides in man and animals. Salt Lake City (UT): University of Utah Press; 1981. p. 273-80.
59. Breitenstein BD. The US Transuranium Registry. In: Wrenn ME, editor. Actinides in man and animals. Salt Lake City, (UT): University of Utah Press; 1981. p. 269-72.
60. Zaire R, Griffin CS, Simpson PJ, Papworth DG, Savage JR, Armstrong S, et al. Analysis of lymphocytes from uranium mine workers in Namibia for chromosomal damage using fluorescence in situ hybridization. Mutat Res 1996;371:109-17.
61. Shanahan EM, Peterson D, Roxby D, Quintana J, Morely AA, Woodward A. Mutation rates at the glycophorin A and HPRT loci in uranium miners exposed to radon progeny. J Occup Environ Med (England) 1966;53:429-32.
62. Conrad K, Mehlhorn J, Luthre K, Dorner T, Frank KH. Systemic lupus erythematosus after heavy exposure to quarz dust in uranium mines: clinical and serological characteristics. Lupus 1996;5:62-7.
63. Zhu SP, Hu QY, Lun MY. Studies on reproductive toxicity of enriched uranium [abstract]. Chun Hoa Yu Fang (China) 1944;28:19.
64. Doucet I. Desert storm syndrome: sick soldiers and dead children. Med War 1994;10:83-4.
65. Korenyi-Both AL, Juncer DJ. Al-Eskan disease: Persian Gulf syndrome. Milit Med 1997;162:1-13.
66. Suzuki T. Zur Morphologie der Nieresekretion unter physioloyischen and pathologischen Bedingungen. Jena: G Fischer; 1912.
67. Oliver J. The histogenesis of chronic uranium nephritis with especial reference to epithelial regeneration. J Exp Med 1915;21:425-51.
68. Hunter VC. Experimental studies of resistance of the rabbit renal epithelium to uranyl nitrate. Ann Intern Med 1928;1:747-89.
69. Jamenbaum A. Toxicology of uranium. New York, Toronto, London: McGraw Hill; 1951.
70. Garnier M, Marke J. L'intoxication chronique par le nitrate d'urane en injection quotidienne chez le lapin. Comptes rendus des seances de la societe de biologie et des filiales (Paris) 1921;107:938-40.
71. Verne J. Lesions histologuiques des centres nerveaux superieurs chez les lapins soumis a l'intoxication chronique par l'urane. Anales des anatomie et pathologie 1931:8;757-8.
72. Jackson DE. On the pharmacological action of uranium. Am J Physiol 1910;26:381-95.
73. Voegtlin C, Hodge HC. Pharmacology and toxicology of uranium compounds. New York, Toronto, London: McGraw Hill; 1949.
74. Aub JC, Evans RD, Hempelman LH, Martland HS. The late effects of internally deposited radioactive materials in man. Medicine (Baltimore) 1952;31:221-329.
75. Karsner HT, Reiman SP. Studies on uranium poisoning, the toxicity of certain water-insoluble salts of uranium. Journal of Medical Research 1918;39:157-61.
76. Sullivan MF. Actinide absorption from the gastrointestinal tract. In: Wrenn ME. Actinides in man and animals. Salt Lake City, (UT): University of Utah Press; 1981 p. 311-36.
77. Harrison JD, Stather JW, Smith H, Stradling GN. The influence of environmental factors on the gastrointestinal absorption of plutonium and americium. In: Wrenn ME. Actinides in man and animals. Salt Lake City (UT): University of Utah Press; 1981. p. 323-36.
78. West S. Further observations on treatment of diabetes mellitus by uranium nitrate. BMJ 1896;11:729-30.
79. Duncan E. The treatment of diabetes mellitus by nitrate of uranium. BMJ 1897;11:1044-7.
80. Sollman T. A manual of pharmacology. London: W.B. Saunders & Co; 1936.
81. Butterworth A. The significance and value of uranium in urine analysis. Transactions of the Association Industrial Medical Officers 1955;5:36-43.
82. Tracey BL, Quinn JM, Lahey J, Gilman AP, Mancuso K, Yagminas AP, et al. Health Phys 1992;62:65-9.
83. Voegtlin C, Hodge HC. Pharmacology and toxicology of uranium compounds. Vol. 3-4. New York; McGraw Hill: 1953.
84. Luesenhop AJ, Gallimore JC, Sweete WH, Struxness EG, Robinson J. The toxicity in man of hexavalent uranium, following intravenous administration. AJR Am J Roentgenol 1958;79:83-100.
85. Terepka AR, Toribara TY, Neuman WF. Skeletal retention of uranium in man. Proceedings of the 46th meeting of the Endocrinology Society, 1964; San Fransisco.
86. Harris WB. The experimental clearance of uranium dust from the human body. In: Davies CN, editor. Inhaled particles and vapours. London: Pergamon Press; 1961. p. 209-17.
87. Morrow PE, Gibb FR, Beiter HD. Inhalation studies of uranium trioxide. Health Phys 1972;23:273-80.
88. Poncy JL, Metivier H, Dhilly M, Verry M, Masse R. In vitro dissolution of uranium oxide by baboon alveolar macrophages. Environ Health Perspect 1992;97:127-9.
89. Baur X, Rihs HP, Altmeyer P, Degens P, Conrad K, Mehlhorn H, et al. Systemic sclerosis in German uranium miners under special consideration of antibody subsets and HLA Class II alleles. Respiration 1996;63:368-74.
90. Crowell RE, Gilliand FD, Temes RT, Harms HJ, Neft RE, Heaphy E, et al. Detection of trisomy 7 in nonmalignant individuals at risk from lung cancer. Cancer Epidemiol Biomarkers Prev 1996;5:631-6.
91. Lyman GH. Risk factors for cancer. Prim Care 1992;19:465-7.
92. Morris KJ, Khanna P, Batchelo AL. Long term clearance of inhaled UO2 particles from the pulmonary region of the rat. Health Phys 1990;58:477-9.
93. Duhamel F, Belayhque M, Pradel J. Organization due controle radiologique dans les mines d'uranium francaises. In: International Atomic Energy Agency. Radiological health and safety in mining and milling of nuclear materials. Vol. 1. Vienna: IAEA;1964. p. 59-63.
94. Breslin AJ, George AC, Weinstein MS. Investigation of radiological characteristics of uranium mine atmospheres. Washington DC: United States Atomic Energy Commission, HASL-220; 1969.
95. Karajovic D, Kilibarda M, Panov D, Djuric D, Medjedovic M, Raicevic P, et al. Uranium in the urine of miners exposed to uranium compounds. In: International Atomic Energy Agency Radiological health and safety in mining and milling of nuclear materials. Vol 2. Vienna: IAEA: 1964; p. 443-50.
96. Booker DV, Chamberlain AC, Newton D, Stoff ANB. Distribution of radioactive lead following inhalation and injection. Br J Radiol 1969;42:457-61.
97. Mishima J, Parkhurst MA, Scherpelz RI, Hadlock DE. Potential behavior of depleted uranium penetrators under shipping and bulk storage accident conditions. Richland (WA): Batelle Pacific Northwest Laboratory; February 1985. Publication PNL-5415, UC-41.
98. Hanson WC. Ecological considerations of depleted uranium munitions. Los Alamos (NM): Los Alamos Scientific Laboratory; 1974 June. Publication LA-5559 U C-11.
99. Bartlett WT, Gilchrist RL, Endres GWR, Baer JL. Radiation characteristics and exposure rate measurements from cartridge 105-MM, APFSDS-T. Richland (WA): Batelle Pacific Northwest Lab; 1979. Publication PNL-2947.
100. Haseltine SD, Sileo L. Response of American black ducks to dietary uranium: a proposed substitute for lead shot. Journal of Wildlife Management 1983;47:1124-7.
101. Egert CM. Aluminum ion plating for corrosion protection of uranium. Oak Ridge (TN): Martin Marietta Energy Systems; 1985. Rev. 1. Y-DV-404.
102. Code of Federal Regulations CFR-10, Chapter 1. Washington DC: Nuclear Regulatory Commission (NRC); 1990.
103. Hursh JB, Neuman NF, Toribara T, Wilson H, Waterhouse C. Oral ingestion of uranium by man. Health Phys 1969;17:619-21.
104. Miller AC, Whittaker T, McBride S, Hogan J, Benson K, Siu H. Biomarkers for carcinogenesis: oncogenic activation by depleted uranium in vivo. Proc Amer Assoc For Cancer Research 1997;38:462
105. Abrams R, Seibert HC, Petts AM, Forker LL, Greenberg D, Postel S, Lohr W. Metabolism of inhaled plutonium in rats [abstract]. Health Phys 1959;2:172-4.
106. Scott KL, Axelrod DJ, Crowley J, Hamilton JG. Deposition and rate of plutonium, uranium and their fission products inhaled as aerosols in rats and man. Archives of Pathology 1949;48:31-54.
107. Recommendations of International Commission on Radiological Protection. Brit J Radiol 1955; Supplement 6: 1-91.
108. Langham WH. Determination of internally deposited radioactive isotopes from excretion analysis. American Industrial Hygiene Association Journal 1956;17:305-11.
109. West CM, Scott LM. Uranium cases showing long chest burden retention. Health Phys 1969;17:781-91.
110. Chambers DR, Markland RA, Clary MK, Bowman RL. Aerosolization characteristics of hard impact testing of depleted uranium penetrators. Aberdeen (MD): Aberdeen Proving Grounds, US Army Armament Research and Development Command, Ballistic Res Lab. 1982. Publication ARBRL-TR-02435.
111. Mercer TT. Definitions of respirable activity. In: McCormick W, editor. Aerosol technology and hazard evaluation. New York: Academic Press; 1973.
112. Ensminger DA, Bucci SA. Procedures to calculate radiological and toxicological exposures from airborne releases of depleted uranium. Washington DC: The Analytical Science Corporation; 1980. Publication TR-3135.
113. Olenik C. The health physics concerns of a typical indoor depleted uranium (DU) firing range [MS Thesis]. Washington DC: Georgetown University; 1990.
114. Evans RD, Goodman C. Determination of the thoron content of air and its bearing on lung cancer hazards in industry. J Industr Hyg 1940;22:89-96.
115. DeVillers AJ, Windish JP. Lung cancer in a fluorspar mining community. I. Radiation, dust and mortality experience. Br J Industr Med 1964;21:94-9.
116. Lundin FE, Wagoner JK, Archer VE. Radon daughter exposures and respiratory cancer, quantitative and temporal aspects. Washington DC: National Institute for Occupational Safety and Health and National Institute of Environmental Health Service; 1971. Joint monograph No. 1.
117. 220Rn from uranium and thorium bearing underground environments. Health Phys 1994;67:60-4.
118. Zaire R, Notter M, Riedel W, Thiel E. Unexpected rates of chromosomal instabilities and alterations of hormone levels in namibian uranium miners. Radiat Res 1997;147:579-82.
119. Leach LJ, Maynard EA, Hodge HC, Scott JK, Yuile CL, Sylvester GE, Wilson HB. A five year inhalational study with natural uranium dioxide (UO2) dust. I. Retention and biologic effects in the monkey, dog and rat. Health Phys 1970;18:599-61.
120. Nonlux WS. Primary pulmonary neoplasms in domestic animals. Southwestern Veterinary Journal 1952;6:131-4.
121. Samet JM, Hornung RW. Review of radon and cancer risk. Risk Anal 1990;19:65-9.
122. Singh NP, Wrenn, ME. Is the beagle dog an appropriate experimental animal for extrapolating data to humans on organ distribution patterns of U, Th and Pu. Health Phys 1989;57;91-7.
123. Saccomano G, Huth GC, Auerbach O, Kuschner M. Relationship of radioactive radon daughters and cigarette smoking in the genesis of lung cancer in uranium miners. Cancer 1988;62:1402-7.
124. Hu QY, Zhu SP. Detection of DNA damage in sperminogenic stages of mice treated with enriched uranyl fluoride by alkaline elution. Radiat Environ Biophys 1990;29:161-7.
125. Lin RH, Wu LJ, Lee CH, Lin Shiau SY. Cytogenetic toxicity of uranyl nitrate in Chinese hamster ovary cells. Mutat Res 1993;319:197-9.
126. Karagas MR, McDonald JA, Greenberg ER, Stukel TA, Weiss JE, Baron JA, et al. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. J Natl Cancer Inst 1996;88:1848-51.
127. Baur X, Marczynski B, Rozynek P, Voss B. Bronchopulmonary precancerous conditions and tumors. Pneumologie 1994;48:825-34.
128. Au WW, Wilkinson GS, Tyning SK, Legator MS, Al Zein R, Hallberg L, et al. Monitoring populations for DNA repair deficiency and for cancer susceptibility. Environ Health Perspect 1996;104 Suppl 3:579-82.
129. Lambert BE. The adequacy of current occupational standards for protecting the health of nuclear workers. Occup Med 1991;6:725-7.
130. Cole LW, Prewett SV, Bonifacio A. Challenges in decontamination of a depleted uranium manufacturing facility. Washington DC: Waste Management Symposium, 1989. Cited from: Olenik CJ. The health physics concerns of a typical indoor depleted uranium (DU) firing range [MS thesis]. Washington DC: Georgetown University; 1990. p. 68-9.
131. Cole LW, Prewett SV, Bonifacio A. Challenges in decontamination of a depleted uranium manufacturing facility. Washington DC: Waste Management Symposium, 1989. Cited from: Olenik CJ. The health physics concerns of a typical indoor depleted uranium (DU) firing range [MS thesis]. Washington DC: Georgetown University; 1990. p. 68-9.
132. Dietz LA. CHEM-434-LAD: Investigation of excess alpha activity observed in recent air filter collections and other environmental samples [Unclassified Technical Report]. Schenectady (NY): Knolls Atomic Power Laboratory; 1980 January.
133. Durakovic A, Hollins JG, Storr MC. The influence of age and sex on the metabolism of americium by rats. Health Phys 1973;24:541-7.
134. Hammond PB, Beliles RP. Metals. In: Casarett LJ, Dull J, editors. Toxicology. The basic science of poisons. 2nd ed. New York: MacMillan Publishing Company; 1980. p. 409-67.
135. Rosen LC, Gur D, Pan SI, Wals N. Long term removal of Am-241 using Ca-DTPA. Health Phys 1989;39:101-6.
136. Catsch A. Diagnosis and treatment of incorporated radionuclides. Vienna: International Atomic Energy Agency; 1976.
137. Lloyd RD, Taylor GN, Boseman JJ, Mays CW, Atherton DR. Further comparison of Ca-DTPA and Zn-DTPA for removal of 241Am from beagles. Health Phys 1979;35:858-62.
138. Balou JE. Preliminary evaluation of several chelating agents for plutonium removal. Health Phys 1962;8:731-6.
139. Taylor GN, Mays CW. Fatal injury induced by Ca-DTPA in dogs. Health Phys 1979;35:858-60.
140. Lushbaugh CC, Washburn LC. FDA-IND Approval for Zn-DTPA, new clinical agent for decorporation therapy of actinides. Health Phys 1979;36:471-2.
141. Volf V, Seidel A, Takada K. Comparative effectiveness of Ca-DTPA, desferroxamine and their combination in removing transuranium elements from rats. Health Phys 1977;32:155-7.
142. Durbin PW, Jeung N, Jones ES, Weitl FL, Raymond KN. Removal of Pu (IV) and Am (III) from mice by LICAMS. Radiat Res 1981;87:387-91.
143. Stradling GN, Stather JN, Ham SE, Sumner SA. The use of puchel and DTPA for removing Pu-239 from the lungs of hamsters. Health Phys 1981;41:387-91.
144. Yatvin MB, Lelkes PI. Clinical prospects for liposomes. Med Phys 1982;9:149-75.
145. Bergeron RJ, Kline SJ. Catecholamide H-shaped ligands as actinide chelators. Radiochem Acta 1984;35:135-42.
146. Vanderbergh PA, Gonzales CF, Wright EM, Kunka BS. Iron-chelating compounds produced by soil pseudomonas: correlation with fungal growth inhibition. Appl Environ Microbiol 1983;46:128-34.
147. Durbin PW, Kullgren B, Xu J, Raymond KN. New agents for in vivo chelation of uranium (VI): efficacy and toxicity in mice of multidentate catecholate and hydroxypyridinonate ligands. Health Phys 1997;72: 865-79.
148. Henge-Napoli MH, Archimbaud M, Ansoborlo E, Metivier H, Gourmelon P. Efficacy of 3, 4, 3-LIHOPO for reducing the retention of uranium in rats after acute administration. Internat J Radiat Biol 1995;68:389-93.